Skip to main content
Premium Trial:

Request an Annual Quote

Aclara and Third Wave Collaborate on Gene Expression Profiling Product, Say Genotyping Next

SAN DIEGO, October 25 — Aclara BioSciences and Third Wave Technologies on Thursday announced a collaboration to develop and commercialize multiplexed gene expression research products that couple Aclara’s eTag sequence-labeling technology with Third Wave's Invader platform. 

The companies said that their combined technologies would enable customers to profile many genes simultaneously in a single reaction directly from crude cell lysates, without the need for sample prep or PCR. 

The first products from the collaboration, to become commercially available immediately through an early access program, will detect and quantify the expression levels of clinically relevant genes, including cytokine and cytochrome P450 genes. Commercialization will begin immediately through an early access program. 

Aclara CEO Joseph Limber said that the Invader platform was appealing for its ability to simultaneously profile many genes directly from crude cell lysates, without sample prep or thermocycling and with superior quantitation and specificity.

The companies said they would also explore the potential for combining their technologies for new genotyping applications. 

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.